Related Experiment Video
Updated: May 9, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
[TRPV1 in neuropathic pain: from animal models to therapeutical prospects]
Aurore Danigo1, Laurent Magy, Claire Demiot
1EA 6309, maintenance myélinique et neuropathies périphériques, faculté de médecine et pharmacie, Limoges Cedex, France.
Abstract:
Since its cloning in 1997, functional and structural studies of TRPV1 have led to an improvement in our understanding of the mechanisms that underlie the transduction of noxious thermal and mechanical stimuli by sensory neurons. Because of its role in inflammatory processes and nociceptive pathways, TRPV1 has become an important target for neuropathic pain relief. Models of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists. Patch and cream containing capsaicin, the most famous TRPV1 agonist, are commercialized to relieve neuropathic pain. Others agonists and TRPV1 antagonists are tested in clinical trials and new agents, "TRPV1 modulators", with fewer side effects are currently developed in experimental studies.
Related Concept Videos
Analgesia and Pain Management
Nociception
Thermosensation
